All blog posts
Total 18 results for
Showing 12 out of 18 results
01 November 2024
EU Commission fines Teva €462.6 million for misuse of divisional patents and disparagement campaign
29 July 2024
Commission investigation into anticompetitive disparagement ends with commitments
24 June 2024
Overview of EU regulatory and competition law in the Pharma sector
19 February 2024
Five Years of Activity in a Priority Sector: The European Commission's Report on Competition Enforcement in the Pharmaceutical Sector (2018-2022)
06 December 2023
Competition law and biosimilars: Time for a new approach or not yet?
31 October 2023
Another chapter in the "pay for delay" saga: General Court rules on the Teva-Cephalon settlement agreement
15 June 2023
Overview of EU and South African regulatory and competition law in the Pharma sector
09 February 2023
Competition law developments in the pharma sector – 2022 round-up and what to expect in 2023
23 November 2022
SANCTION IMPOSED BY THE SPANISH COMPETITION AUTHORITY ON A PHARMA COMPANY FOR MISUSING LITIGATION STRATEGIES REGARDING PATENTS
11 October 2022
Update on the Teva Copaxone EU case. The EU Commission issues a Statement of Objections against Teva over alleged anti-competitive conduct consisting of misuse of divisional patents and a disparagement campaign against its closest competitor
09 February 2022
Competition law in the pharma sector – Developments and what’s to come in 2022
29 March 2021
CJEU CONFIRMS PAY-FOR-DELAY APPROACH AND UPHOLDS DECISION IN LUNDBECK CASES
Showing 12 out of 18 results
View more